Drug Profile
PD 04 - AFFiRis
Alternative Names: a-Syn PD 04; Affitope PD 04; PD04Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Peptide vaccines
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 27 Jul 2021 AC Immune acquires Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs from AFFiRiS
- 28 Oct 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in Austria (Parenteral)
- 08 Sep 2016 Preclinical trials in Parkinson's disease in Austria (Parenteral) before September 2016 (AFFiRis pipeline, September 2016)